Atectura Breezhaler

Country: European Union

Language: Norwegian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

indacaterol acetate, Mometasone furoate

Available from:

Novartis Europharm Limited 

ATC code:

R03AK

INN (International Name):

indacaterol, mometasone

Therapeutic group:

Legemidler for obstruktive sykdommer i luftveiene,

Therapeutic area:

Astma

Therapeutic indications:

Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Product summary:

Revision: 9

Authorization status:

autorisert

Authorization date:

2020-05-30

Patient Information leaflet

                                1
VEDLEGG I
PREPARATOMTALE
2
1.
LEGEMIDLETS NAVN
Atectura Breezhaler 125 mikrogram/62,5 mikrogram inhalasjonspulver,
harde kapsler
Atectura Breezhaler 125 mikrogram/127,5 mikrogram inhalasjonspulver,
harde kapsler
Atectura Breezhaler 125 mikrogram/260 mikrogram inhalasjonspulver,
harde kapsler
2.
KVALITATIV OG KVANTITATIV SAMMENSETNING
Atectura Breezhaler 125 mikrogram/62,5 mikrogram inhalasjonspulver,
harde kapsler
Hver kapsel inneholder 150 mikrogram indakaterol (som acetat) og 80
mikrogram mometasonfuroat.
Hver avgitte dose (dosen som forlater munnstykket på inhalatoren)
inneholder 125 mikrogram
indakaterol (som acetat) og 62,5 mikrogram mometasonfuroat.
Atectura Breezhaler 125 mikrogram/127,5 mikrogram inhalasjonspulver,
harde kapsler
Hver kapsel inneholder 150 mikrogram indakaterol (som acetat) og 160
mikrogram mometasonfuroat.
Hver avgitte dose (dosen som forlater munnstykket på inhalatoren)
inneholder 125 mikrogram
indakaterol (som acetat) og 127,5 mikrogram mometasonfuroat.
Atectura Breezhaler 125 mikrogram/260 mikrogram inhalasjonspulver,
harde kapsler
Hver kapsel inneholder 150 mikrogram indakaterol (som acetat) og 320
mikrogram mometasonfuroat.
Hver avgitte dose (dosen som forlater munnstykket på inhalatoren)
inneholder 125 mikrogram
indakaterol (som acetat) og 260 mikrogram mometasonfuroat.
Hjelpestoff(er) med kjent effekt
Hver kapsel inneholder omtrent 25 mg laktosemonohydrat.
For fullstendig liste over hjelpestoffer, se pkt. 6.1.
3.
LEGEMIDDELFORM
Inhalasjonspulver, hard kapsel (inhalasjonspulver).
Atectura Breezhaler 125 mikrogram/62,5 mikrogram inhalasjonspulver,
harde kapsler
Gjennomsiktige (ufargede) kapsler som inneholder hvitt pulver, med
produktkode «IM150-80» trykket
i blått over en blå linje på hoveddelen, og med produktlogo trykket
i blått mellom to blå linjer på
hetten.
Atectura Breezhaler 125 mikrogram/127,5 mikrogram inhalasjonspulver,
harde kapsler
Gjennomsiktige (ufargede) kapsler som inneholder hvitt pulver, med
produktkode «IM150-160»
trykket i grått på hoveddelen, og
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VEDLEGG I
PREPARATOMTALE
2
1.
LEGEMIDLETS NAVN
Atectura Breezhaler 125 mikrogram/62,5 mikrogram inhalasjonspulver,
harde kapsler
Atectura Breezhaler 125 mikrogram/127,5 mikrogram inhalasjonspulver,
harde kapsler
Atectura Breezhaler 125 mikrogram/260 mikrogram inhalasjonspulver,
harde kapsler
2.
KVALITATIV OG KVANTITATIV SAMMENSETNING
Atectura Breezhaler 125 mikrogram/62,5 mikrogram inhalasjonspulver,
harde kapsler
Hver kapsel inneholder 150 mikrogram indakaterol (som acetat) og 80
mikrogram mometasonfuroat.
Hver avgitte dose (dosen som forlater munnstykket på inhalatoren)
inneholder 125 mikrogram
indakaterol (som acetat) og 62,5 mikrogram mometasonfuroat.
Atectura Breezhaler 125 mikrogram/127,5 mikrogram inhalasjonspulver,
harde kapsler
Hver kapsel inneholder 150 mikrogram indakaterol (som acetat) og 160
mikrogram mometasonfuroat.
Hver avgitte dose (dosen som forlater munnstykket på inhalatoren)
inneholder 125 mikrogram
indakaterol (som acetat) og 127,5 mikrogram mometasonfuroat.
Atectura Breezhaler 125 mikrogram/260 mikrogram inhalasjonspulver,
harde kapsler
Hver kapsel inneholder 150 mikrogram indakaterol (som acetat) og 320
mikrogram mometasonfuroat.
Hver avgitte dose (dosen som forlater munnstykket på inhalatoren)
inneholder 125 mikrogram
indakaterol (som acetat) og 260 mikrogram mometasonfuroat.
Hjelpestoff(er) med kjent effekt
Hver kapsel inneholder omtrent 25 mg laktosemonohydrat.
For fullstendig liste over hjelpestoffer, se pkt. 6.1.
3.
LEGEMIDDELFORM
Inhalasjonspulver, hard kapsel (inhalasjonspulver).
Atectura Breezhaler 125 mikrogram/62,5 mikrogram inhalasjonspulver,
harde kapsler
Gjennomsiktige (ufargede) kapsler som inneholder hvitt pulver, med
produktkode «IM150-80» trykket
i blått over en blå linje på hoveddelen, og med produktlogo trykket
i blått mellom to blå linjer på
hetten.
Atectura Breezhaler 125 mikrogram/127,5 mikrogram inhalasjonspulver,
harde kapsler
Gjennomsiktige (ufargede) kapsler som inneholder hvitt pulver, med
produktkode «IM150-160»
trykket i grått på hoveddelen, og
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-10-2023
Public Assessment Report Public Assessment Report Bulgarian 23-06-2020
Patient Information leaflet Patient Information leaflet Spanish 16-10-2023
Public Assessment Report Public Assessment Report Spanish 23-06-2020
Patient Information leaflet Patient Information leaflet Czech 16-10-2023
Public Assessment Report Public Assessment Report Czech 23-06-2020
Patient Information leaflet Patient Information leaflet Danish 16-10-2023
Public Assessment Report Public Assessment Report Danish 23-06-2020
Patient Information leaflet Patient Information leaflet German 16-10-2023
Public Assessment Report Public Assessment Report German 23-06-2020
Patient Information leaflet Patient Information leaflet Estonian 16-10-2023
Public Assessment Report Public Assessment Report Estonian 23-06-2020
Patient Information leaflet Patient Information leaflet Greek 16-10-2023
Public Assessment Report Public Assessment Report Greek 23-06-2020
Patient Information leaflet Patient Information leaflet English 16-10-2023
Public Assessment Report Public Assessment Report English 23-06-2020
Patient Information leaflet Patient Information leaflet French 16-10-2023
Public Assessment Report Public Assessment Report French 23-06-2020
Patient Information leaflet Patient Information leaflet Italian 16-10-2023
Public Assessment Report Public Assessment Report Italian 23-06-2020
Patient Information leaflet Patient Information leaflet Latvian 16-10-2023
Public Assessment Report Public Assessment Report Latvian 23-06-2020
Patient Information leaflet Patient Information leaflet Lithuanian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-10-2023
Public Assessment Report Public Assessment Report Lithuanian 23-06-2020
Patient Information leaflet Patient Information leaflet Hungarian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 16-10-2023
Public Assessment Report Public Assessment Report Hungarian 23-06-2020
Patient Information leaflet Patient Information leaflet Maltese 16-10-2023
Public Assessment Report Public Assessment Report Maltese 23-06-2020
Patient Information leaflet Patient Information leaflet Dutch 16-10-2023
Public Assessment Report Public Assessment Report Dutch 23-06-2020
Patient Information leaflet Patient Information leaflet Polish 16-10-2023
Public Assessment Report Public Assessment Report Polish 23-06-2020
Patient Information leaflet Patient Information leaflet Portuguese 16-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 16-10-2023
Public Assessment Report Public Assessment Report Portuguese 23-06-2020
Patient Information leaflet Patient Information leaflet Romanian 16-10-2023
Public Assessment Report Public Assessment Report Romanian 23-06-2020
Patient Information leaflet Patient Information leaflet Slovak 16-10-2023
Public Assessment Report Public Assessment Report Slovak 23-06-2020
Patient Information leaflet Patient Information leaflet Slovenian 16-10-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 16-10-2023
Public Assessment Report Public Assessment Report Slovenian 23-06-2020
Patient Information leaflet Patient Information leaflet Finnish 16-10-2023
Public Assessment Report Public Assessment Report Finnish 23-06-2020
Patient Information leaflet Patient Information leaflet Swedish 16-10-2023
Public Assessment Report Public Assessment Report Swedish 23-06-2020
Patient Information leaflet Patient Information leaflet Icelandic 16-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 16-10-2023
Patient Information leaflet Patient Information leaflet Croatian 16-10-2023
Public Assessment Report Public Assessment Report Croatian 23-06-2020